AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
QUEBEC, Canada, October 27 /PRNewswire/ -- AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today announced that it has entered into a license and collaboration agreement with Tulane University, in New Orleans, for the development of Growth Hormone Releasing Hormone (GH-RH) antagonists, a novel class of potential anti-cancer agents.
Under the terms of the agreement, AEterna Zentaris obtained worldwide, exclusive rights to develop and commercialise GH-RH antagonists for all potential indications, including cancer and endocrine disorders, in exchange for research funding, an upfront fee and milestone payments, in addition to royalties on future sales.
GH-RH antagonists represent a potential novel class of promising anti-cancer agents that may offer distinct advantages as compared to other classes of anti-tumor agents, with utility in a variety of tumor types. In addition to their ability to exert…
Source: HighBeam Research, AEterna Zentaris Enters Into a License and Collaboration Agreement...